Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy

被引：0
|
作者：
Delasos, Lukas
Berube, Bryan
Nikoo, Maedeh Zokaei
Wei, Wei
Shapiro, Marc A.
Hassan, Khaled Aref
Stevenson, James
Adjei, Alex A.
Pennell, Nathan A.
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin Fdn, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8611
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [42] Clinical Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with First-Generation EGFR TKIs Followed by Subsequent Osimertinib
    Yao, Y.
    Cheng, J.
    Kang, J.
    Li, X.
    Chen, H.
    Zhou, Q.
    Xu, C.
    Zhang, X.
    Su, J.
    Yan, H.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S671 - S671
  • [43] Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
    Kim, C.
    Xi, L.
    Cultraro, C.
    Wei, F.
    Cheng, J.
    Shafiei, A.
    Pham, T.
    Roper, N.
    Akoth, E.
    Strom, C.
    Tu, M.
    Liao, W.
    Chia, D.
    Morris, C.
    Rajan, A.
    Bagheri, M.
    Jones, G.
    Wong, D.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S366 - S366
  • [44] Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
    Sabari, J.
    Pisano, S.
    Gemmler, K.
    Mueller, J.
    Bernabe Caro, R.
    Girard, N.
    Goto, K.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Lee, S. -H.
    Demirdjian, L.
    Harvey, R.
    Rudolph, S.
    Mahadevia, P.
    Bauml, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S488 - S489
  • [45] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
    Zhou, Q.
    Li, J.
    Wang, J.
    Yang, L.
    Fang, J.
    Dong, X.
    Yi, T.
    Min, X.
    Xu, F.
    Chen, J.
    Zhong, D.
    Bai, J.
    Liu, L.
    Zeng, A.
    Tang, J.
    Wu, H.
    Luo, X.
    Yu, J.
    Su, W.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
  • [46] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [47] Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Fulton, Linnea E.
    Digumarthy, Subba R.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Sequist, Lecia V.
    ACADEMIC RADIOLOGY, 2016, 23 (03) : 329 - 336
  • [48] Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance
    Wang, Jiao-Li
    Wang, Liu-sheng
    Zhu, Jun-qi
    Ren, Jie
    Wang, Di
    Luo, Man
    RESPIROLOGY CASE REPORTS, 2022, 10 (11):
  • [49] Survival Outcome Assessed According to Tumor Burden & Progression Patterns in Patients with EGFR Mutant NSCLC Undergoing EGFR-TKIs
    Cha, Yoon Ki
    Lee, Ho Yun
    Ahn, Myung-Ju
    Choi, Yoon-La
    Lee, Ji Hyun
    Park, Keunchil
    Kim, Seon-Jeong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S277 - S277
  • [50] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
12345